Innovation Pharmaceuticals Inc.
IPIXDrugs in Pipeline
31
Phase 3 Programs
5
Upcoming Catalysts
7
Next Catalyst
Aug 2026
Market Overview
Stock performance and key metrics
7 upcoming, 0 past
Gemcitabine hydrochloride and albumin binding paclitaxel
Locally Advanced Pancreatic Cancer
Cenerimod
Lupus Erythematosus, Systemic
F14
Post Operative Pain
Ivosidenib 500mg
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
0.05% atropine eye drops
Myopia
SOM3355 100mg BID
Huntington's Chorea
Tislelizumab
Glioblastoma Multiforme
S095018
Non-small Cell Lung Cancer (NSCLC)
NTI164
PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
GI-108
Advanced Solid Tumor
THR-184
Acute Kidney Injury
Selatogrel 8 mg
Acute Myocardial Infarction
temelimab 18 mg/kg
Multiple Sclerosis
Bupivacaine HCl
Total Knee Replacement
GNbAC1
Multiple Sclerosis
PRS-344/S095012
Solid Tumor
GI-102 subcutaneous (SC)
Advanced Solid Tumor
Selatogrel
Stable Coronary Artery Disease
SOM0226
Familial Amyloid Polyneuropathy (FAP)
S095035
MTAP-deleted Solid Tumors
SOM3355 200 mg capsules
Huntington Chorea
Ivosidenib
IDH1-mutant Cholangiocarcinoma
S095029
MSI-H/dMMR Gastroesophageal-junction Cancer
Cenerimod 0.5 mg
Systemic Lupus Erythematosus
Furosemide Injection Solution for subcutaneous administration (80 mg)
Heart Failure
Standard of Care (SoC)
COVID-19
GI-101
Advanced Solid Tumor
Kevetrin
Ovarian Cancer
Brilacidin
Head and Neck Neoplasms
400 mg (200 mg BID)
Chronic Stable Plaque Psoriasis
JI-101
Advanced Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Gemcitabine hydrochloride and albumin binding paclitaxel | Phase 3 | Locally Advanced Pancreatic Cancer | - | - |
Cenerimod | Phase 3 | Lupus Erythematosus, Systemic | - | - |
F14 | Phase 3 | Post Operative Pain | - | - |
Ivosidenib 500mg | Phase 3 | Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen | - | - |
0.05% atropine eye drops | Phase 3 | Myopia | - | - |
SOM3355 100mg BID | Phase 2 | Huntington's Chorea | - | - |
Tislelizumab | Phase 2 | Glioblastoma Multiforme | - | - |
S095018 | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | - | - |
NTI164 | Phase 2 | PANS Pediatric Acute-Onset Neuropsychiatric Syndrome | - | - |
GI-108 | Phase 2 | Advanced Solid Tumor | - | - |
THR-184 | Phase 2 | Acute Kidney Injury | - | - |
Selatogrel 8 mg | Phase 2 | Acute Myocardial Infarction | - | - |
temelimab 18 mg/kg | Phase 2 | Multiple Sclerosis | - | - |
Bupivacaine HCl | Phase 2 | Total Knee Replacement | - | - |
GNbAC1 | Phase 2 | Multiple Sclerosis | - | - |
PRS-344/S095012 | Phase 2 | Solid Tumor | - | - |
GI-102 subcutaneous (SC) | Phase 2 | Advanced Solid Tumor | - | - |
Selatogrel | Phase 2 | Stable Coronary Artery Disease | - | - |
SOM0226 | Phase 2 | Familial Amyloid Polyneuropathy (FAP) | - | - |
S095035 | Phase 2 | MTAP-deleted Solid Tumors | - | - |
SOM3355 200 mg capsules | Phase 2 | Huntington Chorea | - | - |
Ivosidenib | Phase 2 | IDH1-mutant Cholangiocarcinoma | - | - |
S095029 | Phase 2 | MSI-H/dMMR Gastroesophageal-junction Cancer | - | - |
Cenerimod 0.5 mg | Phase 2 | Systemic Lupus Erythematosus | - | - |
Furosemide Injection Solution for subcutaneous administration (80 mg) | Phase 2 | Heart Failure | - | - |
Standard of Care (SoC) | Phase 2 | COVID-19 | - | - |
GI-101 | Phase 2 | Advanced Solid Tumor | - | - |
Kevetrin | Phase 2 | Ovarian Cancer | - | - |
Brilacidin | Phase 2 | Head and Neck Neoplasms | - | - |
400 mg (200 mg BID) | Phase 2 | Chronic Stable Plaque Psoriasis | - | - |
JI-101 | Phase 2 | Advanced Solid Tumors | - | - |